The RECORD statement for pharmacoepidemiology (RECORD-PE) checklist of items, extended from the STROBE and RECORD statements, which should be reported in non-interventional

pharmacoepidemiological studies using routinely collected health data

STRORE items

RECORD items

Item	STROBE items	RECORD items	RECORD-PE items	Page	
No				No	
Title and abstract					
1	(a) Indicate the study's design with a commonly used term in the title or the abstract.(b) Provide in the abstract an informative and balanced summary of what was done and what was found.	1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included. 1.2: If applicable, the geographical region and timeframe within which the study took place should be reported in the title or abstract. 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.		1	
Introduc					
	and rationale				
2	Explain the scientific background and rationale for the investigation being reported.	_	_	9	
Objective					
3	State specific objectives, including any prespecified hypotheses.	_	_	10	
Methods					
Study des	<u>. C</u>		A T 1 . 1 . 4 . 1 C . 1	13	
	Present key elements of study design early in the paper.		4.a: Include details of the specific study design (and its features) and report the use of multiple designs if used. 4.b: The use of a diagram(s) is recommended to illustrate key aspects of the study design(s), including exposure, washout, lag and observation periods, and covariate definitions as relevant.	13	
Setting					
5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection.		_	12	
Participa			T		
6	(a) Cohort study—give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up. Case-control study—give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls. Cross sectional study—give the eligibility criteria, and the sources and methods of selection of participants. (b) Cohort study—for matched studies, give matching criteria and number of exposed and unexposed. Case-control study—for matched studies, give matching	6.1: The methods of study population selection (such as codes or algorithms used to identify participants) should be listed in detail. If this is not possible, an explanation should be provided. 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided. 6.3: If the study involved linkage of databases, consider use of a flow	6.1.a: Describe the study entry criteria and the order in which these criteria were applied to identify the study population. Specify whether only users with a specific indication were included and whether patients were allowed to enter the study population once or if multiple entries were permitted. See explanatory document for guidance related to matched designs.	15	

			T	
	criteria and the number of controls per case.	diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.		
Variables	 	550		
7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.	7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an explanation should be provided.	7.1.a: Describe how the drug exposure definition was developed. 7.1.b: Specify the data sources from which drug exposure information for individuals was obtained. 7.1.c: Describe the time window(s) during which an individual is considered exposed to the drug(s). The rationale for selecting a particular time window should be provided. The extent of potential left truncation or left censoring should be specified. 7.1.d: Justify how events are attributed to current, prior, ever, or cumulative drug exposure. 7.1.e: When examining drug dose and risk attribution, describe how current, historical or time on therapy are considered. 7.1.f: Use of any comparator groups should be outlined and justified. 7.1.g: Outline the approach used to handle individuals with more than one relevant drug exposure during the study period.	12-15
Data sour	rces/measurement			
8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group.		8.a: Describe the healthcare system and mechanisms for generating the drug exposure records. Specify the care setting in which the drug(s) of interest was prescribed.	12-13
Bias	more in more union group.		was presented.	
9	Describe any efforts to address potential sources of bias.	_	_	22-23
Study siz	re			
10	Explain how the study size was arrived at.	_		NA
Quantitat	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why.	_		NA
Statistica	ll methods			
12	 (a) Describe all statistical methods, including those used to control for confounding. (b) Describe any methods used to examine subgroups and interactions. (c) Explain how missing data were addressed. (d) Cohort study—if applicable, explain how loss to follow-up was addressed. Case-control study—if applicable, explain how matching of cases and controls was addressed. Cross sectional study—if 		12.1.a: Describe the methods used to evaluate whether the assumptions have been met. 12.1.b: Describe and justify the use of multiple designs, design features, or analytical approaches.	13-14

			T	
	applicable, describe analytical methods			
	taking account of sampling strategy.			
_	(e) Describe any sensitivity analyses.			
	ess and cleaning methods	T	T	
12	_	12.1: Authors should describe the	_	12
		extent to which the investigators		
		had access to the database		
		population used to create the study		
		population.		
		12.2: Authors should provide		
		information on the data cleaning		
		methods used in the study.		
Linkage			1	
12	_	12.3: State whether the study	_	12
		included person level, institutional		
		level, or other data linkage across		
		two or more databases. The		
		methods of linkage and methods of		
		linkage quality evaluation should be		
		provided.		
Results				
Participa				
13	(a) Report the numbers of individuals at	13.1: Describe in detail the	_	15
	each stage of the study (eg, numbers	selection of the individuals included		
	potentially eligible, examined for	in the study (that is, study		
	eligibility, confirmed eligible, included in	population selection) including		
	the study, completing follow-up, and	filtering based on data quality, data		
	analysed).	availability, and linkage. The		
	(b) Give reasons for non-participation at	selection of included individuals		
	each stage.	can be described in the text or by		
	(c) Consider use of a flow diagram.	means of the study flow diagram.		
Descripti				
14	(a) Give characteristics of study	_	_	15-16
	participants (eg, demographic, clinical,			
	social) and information on exposures and			
	potential confounders.			
	(b) Indicate the number of participants			
	with missing data for each variable of			
	interest.			
	(c) Cohort study—summarise follow-up			
0.4	time (eg, average and total amount).			
Outcome	•	T	<u> </u>	16.17
15	Cohort study—report numbers of outcome	_	_	16-17
	events or summary measures over time.			
	Case-control study—report numbers in			
	each exposure category, or summary			
	measures of exposure. Cross sectional			
	study—report numbers of outcome events			
Moin	or summary measures.			
Main resi				16 17
10	(a) Give unadjusted estimates and, if	_	_	16-17
	applicable, confounder adjusted estimates			
	and their precision (eg, 95% confidence intervals). Make clear which confounders			
	were adjusted for and why they were			
i i	included			
	included. (b) Papart catagory boundaries when			
	included. (b) Report category boundaries when continuous variables are categorised.			

		T	-		
	(c) If relevant, consider translating				
	estimates of relative risk into absolute risk				
	for a meaningful time period.				
Other ana		-			
17	Report other analyses done—eg, analyses	_	_	16-17	
	of subgroups and interactions, and				
	sensitivity analyses.				
Discussio	on				
Key resul	lts				
18	Summarise key results with reference to		_	17	
	study objectives.				
Limitatio				.1	
19	Discuss limitations of the study, taking	19.1: Discuss the implications of	19.1.a: Describe the degree to which the	22-23	
-	into account sources of potential bias or	using data that were not created or	chosen database(s) adequately captures		
	imprecision. Discuss both direction and	collected to answer the specific	the drug exposure(s) of interest.		
	magnitude of any potential bias.	research question(s). Include	line drug emposare(o) == ======		
	magnitude of any potential oras.	discussion of misclassification bias,			
	'	unmeasured confounding, missing			
	'	data, and changing eligibility over			
	'	time, as they pertain to the study			
	'	being reported.			
Interpreta	ation .	being reported.	<u>l</u>		
20	Give a cautious overall interpretation of		20.a: Discuss the potential for	17-23	
20	results considering objectives, limitations,	_		17-23	
			confounding by indication,		
	multiplicity of analyses, results from		contraindication or disease severity or		
	similar studies, and other relevant		selection bias (healthy adherer/sick		
	evidence.		stopper) as alternative explanations for		
	'		the study findings when relevant. [A:		
	'		Original text indicated this item was		
			RECORD (ie, not RECORD-PE)?]		
Generalis		т	т		
21	Discuss the generalisability (external		_	22	
	validity) of the study results.				
Other information					
Funding	-	-			
22	Give the source of funding and the role of	_	_	5	
	the funders for the present study and, if				
	applicable, for the original study on which				
	the present article is based.				
Accessibi	pility of protocol, raw data, and programming c	code			
22		22.1: Authors should provide	_	4-5	
	'	information on how to access any			
	'	supplemental information such as			
	'	the study protocol, raw data, or			
	'	programming code.			
	<u> </u>	programming code:		<u>.</u>	

RECORD=reporting of studies conducted using observational routinely collected data; RECORD-PE=RECORD for pharmacoepidemiological research; STROBE=strengthening the reporting of observational studies in epidemiology.

*REFERENCE: Langan SM, Schmidt S, Wing K, Ehrenstein V, Nicholls S, Filion K, Klungel O, Petersen I, Sorensen H, Guttmann A, Harron K, Hemkens L, Moher D, Schneeweiss S, Smeeth L, Sturkenboom M, von Elm E, Wang S, Benchimol EI. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement for Pharmacoepidemiology (RECORD-PE). *BMJ* 2018; 363: k3532.